Is the blockbuster model dead? Turna Ray, who writes GT’s sister publication Pharmacogenomics Reporter, posited that this might be the case for big pharma, which hopes to one day sell therapies more aligned with personalized treatment. There seems to be growing consensus: Chris Anderson, editor of Wired and author of the 2006 book, The Long Tail, blogged a few days ago about a New England Journal of Medicine article that ponders the potential demise of the one-size-fits-all blockbuster.
Blockbuster Drugs...So Last Century?
Apr 03, 2007